轉錄組學市場－全球產業規模、佔有率、趨勢、機會和預測，按組件、技術、應用、最終用戶、地區和競爭細分，2020 年至 2030 年

2024年，全球轉錄組學市場規模達75.3億美元，預計2030年將達102.8億美元，預測期內複合年成長率為5.33%。全球轉錄組學市場正經歷顯著成長，這得益於發展中國家RNA定序和NGS在遺傳疾病診斷中的應用日益廣泛。此外，隨著新型微陣列技術的引入，政府機構對新技術開發的積極性和投資不斷增加，並顯著增加了全球各地對轉錄組學的需求。此外，新技術的普及和個人化醫療治療需求的不斷成長，預計將進一步增加對轉錄組學的需求，從而推動市場成長。

此外，生物製藥公司數量的不斷成長以及研發支出的不斷增加，預計將進一步增加對轉錄組學的需求，從而支持市場成長。在美國，每年每4.5分鐘就有一名嬰兒出生時患有先天缺陷，每33名美國新生兒中就有1名患有先天缺陷，這意味著大約有12萬名嬰兒受到影響。轉錄組學是研究轉錄組的學科，而轉錄組則是由基因組產生的一整套RNA轉錄物。

關鍵市場促進因素

高通量定序技術的進展

主要市場挑戰

複雜的數據解釋和生物資訊瓶頸

主要市場趨勢

多組學方法在疾病研究中的整合

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：臨床試驗分析

第6章：全球轉錄組學市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按組件（儀器、耗材、軟體和服務）
  • 依技術（次世代定序、聚合酶鍊式反應、微陣列、原位雜合技術、其他）
  • 按應用（藥物發現與開發、細胞生物學、單細胞分析、基因表現、其他）
  • 按最終用戶（生物技術與製藥公司、學術與研究機構、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按組件
  • 依技術
  • 按應用
  • 按最終用戶
  • 按地區

第7章：北美轉錄組學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第8章：歐洲轉錄組學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第9章：亞太轉錄組學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第10章：南美洲轉錄組學市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 11 章：中東和非洲轉錄組學市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 12 章：市場動態

• 驅動程式
• 挑戰

第13章：市場趨勢與發展

• 最新動態
• 併購
• 產品發布

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品/服務的威脅

第 15 章：SWOT 分析：全球轉錄組學市場

第 16 章：競爭格局

• Agilent Technologies, Inc.
• ANGLE plc.
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson, and Company
• Fluidigm Corporation
• BioSypder, Inc.
• Danaher Corporation
• 10x Genomics, Inc.
• Pacific Biosciences of California, Inc.
• NanoString Technologies, Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

Global Transcriptomics Market was valued at USD 7.53 billion in 2024 and is expected to reach USD 10.28 billion by 2030 with a CAGR of 5.33% during the forecast period. The global market for Transcriptomics is experiencing significant growth, driven by the growing application of RNA sequencing and NGS for the diagnosis of genetic illness in the developing countries. Additionally, growing initiative and investments by government organizations for developing new technology, with the introduction of new microarray technology have significantly increased the demand for transcriptomics across different parts of the globe. Additionally, the rising adoption of new technology and growing demand for personalized medicine for treatments are further expected to increase the demand for transcriptomics, thereby fuelling the market growth.

Furthermore, increasing number of biopharmaceutical companies and growing expenditure on research and development are further expected to increase the demand for transcriptomics, thereby supporting the market growth. Every 4 1/2 minutes, a baby is born with a birth defect in United States every year and affects 1 in every 33 babies born in the United States each year. That translates into about 120,000 babies. Transcriptomics is the study of the transcriptome, which is the complete set of RNA transcripts that are produced by the genome.

Key Market Drivers

Advancements in High-Throughput Sequencing Technologies

The rapid evolution and increased affordability of high-throughput sequencing technologies-particularly RNA sequencing (RNA-seq)-have significantly propelled the growth of the global transcriptomics market. RNA-seq enables the precise quantification of transcripts and discovery of novel RNA species across various sample types, thereby facilitating large-scale gene expression profiling in both basic research and clinical applications. Governments across the globe are investing heavily in next-generation sequencing (NGS) infrastructure. For instance, the U.S. National Institutes of Health (NIH) allocated over $1.5 billion in 2023 for initiatives linked to genomic medicine, including transcriptomics. NIH's All of Us Research Program has specifically emphasized the inclusion of RNA expression data to understand disease biology across diverse populations.

In addition, transcriptomics technologies are increasingly integrated into disease biomarker discovery, drug development pipelines, and personalized medicine. Projects such as the Genotype-Tissue Expression (GTEx) Project by the NIH have generated comprehensive gene expression datasets, enabling researchers to map tissue-specific gene expressions and variation across populations. The plummeting costs of RNA-seq-from over $1,000 per sample a decade ago to less than $100 today-have democratized access to these technologies. This price drop is particularly impactful for academic institutions and biotech companies in developing nations, driving adoption at a global scale. Moreover, automation in sample preparation, data analysis, and bioinformatics pipelines further accelerates throughput and reduces labor costs, enhancing scalability.

Key Market Challenges

Complex Data Interpretation and Bioinformatics Bottlenecks

Despite the advances in transcriptomic technologies, data complexity and bioinformatics limitations remain substantial challenges hindering market growth. Transcriptomic analyses-especially using RNA-seq-generate enormous volumes of data, often reaching hundreds of gigabytes per sample. Extracting meaningful insights from these datasets requires sophisticated algorithms, powerful computational infrastructure, and expertise in bioinformatics. The European Bioinformatics Institute (EMBL-EBI) and NIH's National Center for Biotechnology Information (NCBI) host large-scale transcriptomic repositories such as GEO (Gene Expression Omnibus) and ArrayExpress. However, interpreting this data requires integration with proteomics, genomics, and clinical phenotypes, which adds further layers of complexity. For many healthcare providers and small research labs, this technical requirement becomes a major barrier.

According to a 2022 survey by the Global Alliance for Genomics and Health (GA4GH), more than 60% of genomics labs identified a shortage of bioinformatics talent as a significant operational bottleneck. Furthermore, inconsistencies in data normalization, quality control, and analysis pipelines often lead to irreproducible results, limiting the translational utility of transcriptomics in clinical settings. Another related challenge is the need for standardized bioinformatics workflows. While initiatives such as the FDA's SEQC (Sequencing Quality Control) Project aim to establish quality benchmarks, globally accepted standards for transcriptomic data interpretation are still evolving. Until data analysis becomes more user-friendly and standardized across platforms, the complexity of transcriptomic datasets will continue to restrain broader adoption in clinical and research domains.

Key Market Trends

Integration of Multi-Omics Approaches in Disease Research

A growing trend in transcriptomics is its integration with other omics technologies, including genomics, proteomics, epigenomics, and metabolomics, to provide a holistic view of biological systems. This multi-omics approach enhances the understanding of complex disease mechanisms by correlating gene expression profiles with protein activity, epigenetic modifications, and metabolic changes. The U.S. National Cancer Institute (NCI) has launched several multi-omics initiatives, including the Human Tumor Atlas Network (HTAN), which maps tumors using transcriptomics, genomics, and imaging. The goal is to understand how tumors evolve over time and how patients respond to therapy, enabling the development of personalized treatment plans.

Similarly, the UK Biobank, backed by the UK government and Wellcome Trust, is increasingly adding transcriptomic data to its already vast genomic and clinical dataset. This allows researchers to connect gene expression patterns with real-world disease outcomes in a population-scale setting. This trend is not limited to developed countries. India's GenomeIndia project, supported by the Department of Biotechnology, is also moving towards the integration of transcriptomics with proteomic and metabolomic data to understand ethnic-specific disease vulnerabilities. Such integrative research helps in discovering novel drug targets, stratifying patients for clinical trials, and predicting disease progression. With advancements in artificial intelligence (AI) and machine learning (ML), multi-omics data integration is becoming more feasible, driving deeper biological insights and fueling demand for transcriptomic technologies.

Key Market Players

• Agilent Technologies, Inc.
• ANGLE plc.
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson, and Company
• Fluidigm Corporation
• BioSypder, Inc.
• Danaher Corporation
• 10x Genomics, Inc.
• Pacific Biosciences of California, Inc.
• NanoString Technologies, Inc.

Report Scope:

In this report, the Global Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transcriptomics Market, By Component:

• Instruments
• Consumables
• Software & Services

Transcriptomics Market, By Technology:

• Next Generation Sequencing
• Polymerase Chain Reaction
• Microarray
• In-Situ Hybridization
• Others

Transcriptomics Market, By Application:

• Drug Discovery & Development
• Cell Biology
• Single Cell Analysis
• Gene Expression
• Others

Transcriptomics Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Transcriptomics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Transcriptomics Market.

Available Customizations:

Global Transcriptomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Transcriptomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component (Instruments, Consumables, Software & Services)
  • 6.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Microarray, In-Situ Hybridization, Others)
  • 6.2.3. By Application (Drug Discovery & Development, Cell Biology, Single Cell Analysis, Gene Expression, Others)
  • 6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Component
  • 6.3.2. By Technology
  • 6.3.3. By Application
  • 6.3.4. By End User
  • 6.3.5. By Region

7. North America Transcriptomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Transcriptomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Canada Transcriptomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Mexico Transcriptomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User

8. Europe Transcriptomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Transcriptomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Transcriptomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. United Kingdom Transcriptomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Transcriptomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Spain Transcriptomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Asia-Pacific Transcriptomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Transcriptomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. India Transcriptomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Japan Transcriptomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User
  • 9.3.4. South Korea Transcriptomics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Component
      • 9.3.4.2.2. By Technology
      • 9.3.4.2.3. By Application
      • 9.3.4.2.4. By End User
  • 9.3.5. Australia Transcriptomics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Component
      • 9.3.5.2.2. By Technology
      • 9.3.5.2.3. By Application
      • 9.3.5.2.4. By End User

10. South America Transcriptomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Transcriptomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Transcriptomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Transcriptomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Middle East and Africa Transcriptomics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Component
  • 11.2.2. By Technology
  • 11.2.3. By Application
  • 11.2.4. By End User
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Transcriptomics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Component
      • 11.3.1.2.2. By Technology
      • 11.3.1.2.3. By Application
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Transcriptomics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Component
      • 11.3.2.2.2. By Technology
      • 11.3.2.2.3. By Application
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Transcriptomics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Component
      • 11.3.3.2.2. By Technology
      • 11.3.3.2.3. By Application
      • 11.3.3.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Transcriptomics Market

16. Competitive Landscape

• 16.1. Agilent Technologies, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. ANGLE plc.
• 16.3. Bio-Rad Laboratories, Inc.
• 16.4. Becton, Dickinson, and Company
• 16.5. Fluidigm Corporation
• 16.6. BioSypder, Inc.
• 16.7. Danaher Corporation
• 16.8. 10x Genomics, Inc.
• 16.9. Pacific Biosciences of California, Inc.
• 16.10. NanoString Technologies, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer